NCT04480541 is a NA clinical trial of Roadmap 2.0 information system in Cancer, sponsored by University of Michigan Rogel Cancer Center.

Who is sponsoring NCT04480541?

NCT04480541 is sponsored by University of Michigan Rogel Cancer Center.

What drugs are being tested in NCT04480541?

Interventions in NCT04480541: Roadmap 2.0 information system, Wearable activity sensor, Survey administration.

What condition does NCT04480541 study?

NCT04480541 studies Cancer, Quality of Life.

Is NCT04480541 still recruiting?

NCT04480541 is currently completed. Last updated 29 November 2023.

Last reviewed 2023-11-29 · How we verify

NCT04480541

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Pilot Study of Roadmap 2.0 in Oncology Caregivers and Patients

Completed NA Last updated 29 November 2023

What this trial tests

NA trial testing Roadmap 2.0 information system in Cancer in 138 participants. Completed in 20 June 2023.

Timeline

18 September 2020

Primary endpoint
20 June 2023

20 June 2023

Quick facts

Lead sponsor	University of Michigan Rogel Cancer Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	health services research
Enrollment	138
Start date	18 September 2020
Primary completion	20 June 2023
Estimated completion	20 June 2023
Sites	1 location across United States

Drugs / interventions tested

Roadmap 2.0 information system
Wearable activity sensor
Survey administration

Conditions studied

Cancer — all drugs for Cancer →
Quality of Life — all drugs for Quality of Life →

Sponsor

University of Michigan Rogel Cancer Center

Who can join

5 and older, any sex, with Cancer or Quality of Life. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will investigate the use of a mobile health app (Roadmap 2.0) intervention in caregivers of patients with cancer. In this study participants will be given the Roadmap 2.0 app, with a focus on the positive aspects of caregiving (positive activity components), and a Fitbit. The primary objective of this pilot study is to test the feasibility and acceptability of using the mobile health app.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Integrating Artificial Intelligence-Driven Wearable Technology in Oncology Decision-Making: A Narrative Review.
Birla M, Rajan, Roy PG, Gupta I, et al · · 2025 · cited 14× · PMID 39072365 · DOI 10.1159/000540494
A pilot intervention of using a mobile health app (ONC Roadmap) to enhance health-related quality of life in family caregivers of pediatric patients with cancer.
Koblick SB, Yu M, DeMoss M, Liu Q, et al · · 2023 · cited 6× · PMID 36760786 · DOI 10.21037/mhealth-22-24
Stakeholder engagement, proper planning and modular design for mHealth apps: lessons from QuestExplore and working toward standards for mHealth app design.
Johnson AK, Choi SW. · · 2022 · cited 2× · PMID 36338312 · DOI 10.21037/mhealth-22-28

Verify or expand the search:

Other trials of Roadmap 2.0 information system

Trials testing the same drug.

NCT04094844 — Health Information Technology System ("Roadmap 2.0") in the Context of Hematopoietic Cell Transplantation · NA · completed

Other recruiting trials for Cancer

Currently open trials in the same condition.

NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting

Other University of Michigan Rogel Cancer Center trials

Trials by the same sponsor.

NCT06914479 — Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and · Phase 1 · recruiting
NCT07481344 — SunBeast: Evaluating UV Protective Behaviors and Education Interventions Among Ultrarunners · NA · not yet recruiting
NCT07526545 — Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial · NA · not yet recruiting
NCT07443943 — A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive · Phase 2 · recruiting
NCT07365007 — A Virtually Delivered Diet Intervention (LASO-3) for the Improvement of Chemotherapy-Induced Peripheral Neuropathy in Ca · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04480541 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Michigan Rogel Cancer Center
Last refreshed: 29 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04480541.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing